Determining tigecycline's in vitro activity multidrug-resistant Enterobacteriaceae from the T.E.S.T. Program – Global Data

Abstract number: p1316

Johnson  B., Bouchillon  S., Stevens  T., Johnson  J., Hoban  D., Dowzicky  M.


Tigecycline, a member of a new class of antimicrobials (glycylcyclines), has been shown to have potent expanded broad spectrum activity against most commonly encountered species responsible for community and hospital acquired infections including GN, GP, Anaerobic and resistant strains. The T.E.S.T. program determined the in vitro activity of tigecycline compared to amoxicillin-clavulanic acid, piperacillin-tazobactam, levofloxacin, ceftriaxone, cefepime, ampicillin, amikacin, minocycline, ceftazidime and imipenem against Enterobacteriaceae species collected from hospitals globally throughout 2004–2006. The objective of this study was to evaluate the activity of tigecycline against multi-resistant microorganisms, commonly associate with nosocomial infections.


A total of 9231 clinical Enterobacteriaceae were identified to the species level at each site and confirmed by the central laboratory. Minimum Inhibitory Concentration (MICs) were determined by each site using supplied broth microdilution panels and interpreted according to CLSI guidelines. Tigecycline breakpoint (FDA, 2005) is defined as susceptible MICs <=2 mcg/ml.


As expected, different resistance patterns were detected among Enterobacteriaceae sampled in this study. As shown in the table below, tigecycline presented excellent inhibitory activity against all resistance phenotypes encountered.


Multi-drug resistance is often seen in health care acquired pathogens. The presented data suggest that tigecycline is highly potent against nosocomial or community pathogens regardless to the resistance patterns in these selected strains of Enterobacteriaceae.

Session Details

Date: 01/08/2007
Time: 00:00-00:00
Session name: XXIst ISTH Congress
Location: Oxford, UK
Presentation type:
Back to top